title: Enhanced sealing strength of a hydrophobically-modified Alaska pollock gelatin-based sealant.
abstract: The aim of this study was the development of an innovative biocompatible sealant composed of Alaska pollock-derived gelatin partially modified with a dodecyl group (C12-ApGltn) and a poly(ethylene glycol)-based crosslinker, pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate. The burst strength of the developed sealants was measured using porcine aorta and rat lungs. The maximum burst strength of a C12-ApGltn-based sealant against the porcine aorta was 4-fold higher than that of an original ApGltn (Org-ApGltn)-based sealant. No significant increase in the burst strength was observed between C12-ApGltn-based sealants with 4.2 and 8.9 mol% modification ratios. From histological observation after burst strength measurement, tissue tearing was observed when a C12-ApGltn-based sealant was applied. In contrast, the Org-ApGltn-based sealant was peeled away from the aorta surface due to cohesion failure. Similar to the porcine aorta, the burst strength of C12-ApGltn-based sealants applied on a rat lung defect was 3-fold higher than that of an Org-ApGltn-based sealant. The curing time of the C12-ApGltn-based sealant measured by a simple mixing method was shorter (2.6 ± 0.1 s) than that of the Org-ApGltn-based sealant (4.1 ± 0.3 s). The swelling ratio of the C12-ApGltn-based sealant (23.7 ± 3.1) was significantly lower than that of the Org-ApGltn-based sealant (32.3 ± 1.1). The C12-ApGltn-based sealant was completely degraded within 28 days after implantation in the backs of rats without a severe inflammation reaction. However, the Org-ApGltn-based sealant disappeared within 14 days. These results indicated that hydrophobically-modified ApGltn has an effective sealing effect on moist tissues and biocompatibility in vivo.
authors.affiliation: Graduate School of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Mizuno
authors.forename: R
authors.initials: R
authors.lastname: Mizuta
authors.forename: M
authors.initials: M
authors.lastname: Hashizume
authors.forename: T
authors.initials: T
authors.lastname: Taguchi
mesh_terms: D000413:Alaska; D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry* / Q000627:therapeutic use; D003432:Cross-Linking Reagents / Q000737:chemistry / Q000627:therapeutic use; D048388:Gadiformes / Q000378:metabolism; D005780:Gelatin / Q000737:chemistry* / Q000627:therapeutic use; D005977:Glutarates / Q000737:chemistry* / Q000627:therapeutic use; D057927:Hydrophobic and Hydrophilic Interactions; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000627:therapeutic use; D051381:Rats; D013552:Swine; D013718:Tensile Strength; D014014:Tissue Adhesives / Q000737:chemistry* / Q000627:therapeutic use
chemical_list: D001672:Biocompatible Materials; D003432:Cross-Linking Reagents; D005977:Glutarates; D014014:Tissue Adhesives; C499599:pentaerythritol poly(ethylene glycol) ether tetrasuccinimidyl glutarate; D011092:Polyethylene Glycols; D005780:Gelatin